Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1

被引：0
|
作者：
Tyring, S. [1 ]
Spelman, L. [2 ,3 ]
Igarashi, A. [4 ]
Ohtsuki, M. [5 ]
Li, Q. [6 ]
Mendelsohn, A. [7 ]
Parno, J. [7 ]
Guenthner, S. [8 ]
机构：
[1] Univ Texas Houston, Dept Dermatol, UTHlth, Houston, TX USA
[2] Verac Clin Res, Brisbane, Qld, Australia
[3] Prob Med Res, Waterloo, ON, Canada
[4] NNT Med Ctr Tokyo, Tokyo, Japan
[5] Jichi Med Univ Hosp, Shimotsuke, Tochigi, Japan
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Sun Pharmaceut Ind Inc, Princeton, NJ USA
[8] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 2
    Gooderham, M.
    Papp, K.
    Blauvelt, A.
    Thaci, D.
    Li, Q.
    Mendelsohn, A.
    Parno, J.
    Reich, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 62
  • [2] Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1
    Crowley, Jeffrey
    Korman, Neil J.
    Spelman, Lynda
    Igarashi, Atsuyuki
    Gupta, Aditya K.
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Eads, Kimberly M.
    Guenthner, Scott T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB162 - AB162
  • [3] Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 2
    Langley, Richard G.
    Gooderham, Melinda
    Papp, Kim Alexander
    Yamauchi, Paul
    Thaci, Diamant
    Parno, Jeff
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB163 - AB163
  • [4] Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1)
    Imafuku, Shinichi
    Nakagawa, Hidemi
    Igarashi, Atsuyuki
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Tada, Yayoi
    Nemoto, Osamu
    Rozzo, Stephen J.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 844 - 852
  • [5] Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1)
    Igarashi, Atsuyuki
    Nakagawa, Hidemi
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Imafuku, Shinichi
    Tada, Yayoi
    Honma, Masaru
    Mendelsohn, Alan M.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 853 - 863
  • [6] Efficacy responses with tildrakizumab in moderate-to-severe chronic plaque psoriasis patients with previous exposure to apremilast: Results of a pooled analysis of reSURFACE 1 and reSURFACE 2
    Gordon, Kenneth
    Reich, Kristian
    Pariser, David
    Menter, Alan
    Tyring, Stephen K.
    Sofen, Howard
    Rozzo, Stephen
    Parn, Jeffrey
    Li, Qing
    La Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB125 - AB125
  • [7] Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis
    Langley, R
    Leonardi, C
    Toth, D
    Chen, D
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P2 - P2
  • [8] Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study
    Okubo, Yukari
    Ohtsuki, Mamitaro
    Morita, Akimichi
    Yamaguchi, Masako
    Shima, Tomohiro
    Tani, Yumiko
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2019, 46 (03): : 186 - 192
  • [9] Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials
    Elewski, Boni
    Han, George
    Rozzo, Stephen J.
    Gogineni, Ranga
    Schenkel, Brad
    Guenthner, Scott
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB57 - AB57
  • [10] Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks
    Reich, K.
    Warren, R. B.
    Iversen, L.
    Puig, L.
    Pau-Charles, I.
    Igarashi, A.
    Ohtsuki, M.
    Falques, M.
    Harmut, M.
    Rozzo, S.
    Lebwohl, M. G.
    Cantrell, W.
    Blauvelt, A.
    Thaci, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (03) : 605 - 617
12345